Astec Lifesciences Ltd Q2 FY22 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 2- →Astec LifeSciences expects annualized sales growth of 15%-20% for FY2022.
- →Volume growth in H1 FY2022 was about 11%.
- →Enterprise sales value growth is targeted at 20%-25% this year, driven by 10%-15% volume growth.
- →CMO business is projected to grow at a compounded annual rate of 50% over the next three years.
- →CMO contribution is expected to rise gradually, with herbicide plant ramp-up increasing CMO capacity utilization from 30% this year to higher next year.
- →New product introductions: 4 CMO products and 1 enterprise product this year; 2 more enterprise products expected in FY2023.
- →Full utilization of the herbicide plant expected to reach 100% by the third year, currently at 30%-35% utilization.
- →Future growth also supported by backward integration and new fungicide plant investments.
- →Pricing improvements and better realizations expected to aid revenue growth despite some short-term production losses.
See what Astec Lifesciences Ltd management said on margin guidance — free account, 30 seconds.
Fundraise plans
- →The company has not explicitly mentioned any current or future fundraising plans through debt or equity in the provided transcript.
- →However, Ashok Hiremath indicated that recent evaluations suggest the planned investment figure (capex) may go up.
- →They are prepared to be more aggressive with investment plans in the future, which may imply potential future capital raising.
- →Currently, the company is borrowing at very low rates (4.1%) and leveraging working capital efficiently to improve profitability.
- →The planned capex is Rs.150 Crore for the current year and Rs.300-350 Crore over a 2-3 year window, with possibility of an upward revision.
- →No mention was made of any specific equity raising or debt issuance underway or planned.
See what Astec Lifesciences Ltd management said on order book — free account, 30 seconds.
Capex plans
Yes- →Capex plan for FY2022 is on track with an expected spend of Rs.150 Crore.
- →Investments include completion of the new herbicide facility and ongoing construction of a new fungicide plant.
- →A new state-of-the-art R&D center is under construction, expected to be completed by the end of FY2023; currently, additional R&D capacities have been hired externally.
- →Future capex estimates over a 2-3 year window are expected to be in the Rs.300-350 Crore range, with potential to increase as per recent evaluations.
- →The company plans to be aggressive with capital investments to expand product portfolios and capacity.
- →Modifications are being planned at the Mahad facility to mitigate flooding risk due to climate change effects.
Track Astec Lifesciences Ltd — get its next earnings analysis in your feed
Margin guidance
Category 1- →Astec LifeSciences targets annualized revenue growth of 15%-20% as a general guidance.
- →EBITDA margins expected to improve from about 22% to 24% over coming years due to higher CMO business contribution, which commands ~5% better margins than enterprise sales.
- →The company anticipates a 50% growth in CMO business in FY2023 as new herbicide and fungicide products ramp up.
- →Enterprise business volume growth expected at 10%-15% with 20%-25% value growth in the current year.
- →Pricing pressures on key products are easing, with improved realizations expected, particularly in H2 FY2022.
- →Backward integration and price hikes are expected to contribute positively to margins going forward.
- →New product introductions: 4 CMO products plus 1 enterprise product this year, and 2 enterprise products (triazole fungicides) expected commercially by Q4 FY2023.
- →Capex planned at Rs.150 crore this year, potentially increasing to support growth initiatives.
Order book
- →As of the call dated October 28, 2021, specific details about the current order book or pending orders were not directly disclosed.
- →Ashok Hiremath mentioned variability in Contract Manufacturing Organization (CMO) business depending on campaign-wise production with orders varying year-to-year.
- →There was mention of around Rs.29.5 Crore of revenue deferred from Q2 to Q3 due to shipment delays.
- →The CMO business experienced a lower contribution in H1 FY2022 but is expected to grow significantly (about 50% CAGR) over the next three years.
- →The herbicide plant started production in August and is on track to reach 30%-35% capacity utilization in the first year, progressing towards full capacity by the third year.
- →The company is working on several new products (4 CMO and 1 enterprise in the current year, and 2 more enterprise products next year) which indicate order inflow in the near term.
- →Management expressed aspirations to increase the CMO business proportion to around 40% in coming years.
How does Astec Lifesciences Ltd rank vs peers in Fertilizers & Agrochemicals?
Pro featureSee full Fertilizers & Agrochemicals sector rankings
How does Astec Lifesciences Ltd rank in Fertilizers & Agrochemicals?
Compare Astec Lifesciences Ltd against every Fertilizers & Agrochemicals company (Q2 FY22) on revenue, margins and earnings-call signals.
Continue your research
What Astec Lifesciences Ltd's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- GSP Crop Science (Q1 FY27)
Capacity utilization indicates room for growth: 70-75% for technical and 25-30% for formulations. Key concall takeaways from GSP Crop Science Ltd's Q1 FY27…
- Sharda Cropchem (Q4 FY25)
Globally, the company’s current 4%-5% global market share offers scope to increase, meaning a 1% global share gain equates to 20%-25% volume growth for them…
- Sumitomo Chemi. (Q2 FY26)
Domestic sales grew 11% YoY in H1 FY '25-'26, with improved farmer connect initiatives like 'Every Day Farmers Day' enhancing demand. Key concall takeaways…
- Indogulf Cropsci (Q3 FY26)
The value of these export orders in hand is approximately INR 4 to 5 crores. Key concall takeaways from Indogulf Cropsci's Q3 FY26 earnings call — and how it…